Ag-specificity within the ACI platform could be achieved by introducing tumor-infiltrating lymphocyte (TIL) or genetically modified T cells such as TCR engineered T cells (TCR-T) and chimeric Ag receptor-engineered T cells (CAR-T) that recognize tumor-associated Ags in a MHC-dependent and independent manner [26]. The gene discussed is JAG1; the disease is neoplasm.